Suppression of endometriosis and its associated symptoms remains a major global unmet need. Efficacy of peptide IK14004 in the management of this estrogen-dependent chronic inflammatory condition is currently being assessed in vivo including its effects on immune cells isolated from endometriosis-affected women.
Immunomodulation by IK14004 is described in a recent article in the Australian and New Zealand Journal of Obstetrics and Gynaecology
An Immunomodulating Peptide With Potential to Counteract Endometriosis

InterK Peptide Therapeutics Ltd. owns full rights and title to intellectual property associated with the structure of compound IK14004 including its enablement as complementary therapy in the management of endometriosis.